Privately held biotech Defender Pharmaceuticals’ lead candidate, DPI-386, has met the primary endpoint in a Phase III motion sickness trial, sparking plans for a new drug application as the firm simultaneously explores other applications of scopolamine.
Defender’s Scopolamine Nasal Gel Secures Pivotal Win In Motion Sickness
Could Challenge Bayer’s Patch
The US firm’s nasal gel formulation of the anticholinergic compound has succeeded in a second Phase III trial, bringing Defender closer to entering a market dominated by Bayer’s Transderm Scop.
More from Clinical Trials
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from R&D
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.